First Tracks Biotherapeutics (TRAX) — Cash Flow-to-Debt Ratio
First Tracks Biotherapeutics (TRAX) has a Cash Flow-to-Debt Ratio of -0.98x as of March 2026, meaning its operating cash flow of $-32.56 Million could theoretically repay -1% of its total liabilities ($33.11 Million) in one year. Explore First Tracks Biotherapeutics (TRAX) long-term investment share to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
First Tracks Biotherapeutics Cash Flow-to-Debt Ratio (2023–2025)
Historical debt coverage capacity for First Tracks Biotherapeutics across 3 annual periods. Also explore First Tracks Biotherapeutics asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for First Tracks Biotherapeutics (2023–2025)
Year-by-year debt coverage analysis for First Tracks Biotherapeutics. For market capitalisation and broader financial context, see First Tracks Biotherapeutics market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.32x | $-142.93 Million | $43.05 Million | ▼ -32.7% |
| 2024 | -2.50x | $-125.81 Million | $50.30 Million | ▲ +7.9% |
| 2023 | -2.71x | $-93.00 Million | $34.26 Million | — |